Finished
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting
NCT07050875 · ABLE Human Motion S.L. · Updated 27 Jan 2026
- What is being tested
- ABLE Exoskeleton
- For
- Acquired Brain Injury (Including Stroke)
- Kind of study
- Tests a treatment or device on volunteers. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 14 people. The full rules are on the registry page.
- Where
- Spain (3 sites)
- When
- Starts or started 30 June 2025, ends 17 Dec 2025. Registered 3 July 2025.
- Results
- None posted yet.
In the researchers' words
The primary objective of the study is to validate the safety and clinical performance of the ABLE Exoskeleton device in people with acquired brain injury during a 10-session gait training program in a clinical setting. The secondary objective of the study focuses on obtaining preliminary data on the potential clinical and psychosocial benefits of the product.
Sites
- Cefine Neurología (CEFINE)Culleredo, A Coruña, Spain
- Fundación Step by StepL'Hospitalet de Llobregat, Barcelona, Spain
- Centro Europeo de Neurociencias (CEN)Madrid, Madrid, Spain